Scarica l'app Stockscreener
6.85
1.72%
-0.12
Dopo l'orario di chiusura:
6.85
Precedente Chiudi:
$6.97
Aprire:
$6.94
Volume 24 ore:
268.97K
Relative Volume:
0.72
Capitalizzazione di mercato:
$455.21M
Reddito:
$555.06M
Utile/perdita netta:
$-39.48M
Rapporto P/E:
-11.42
EPS:
-0.6
Flusso di cassa netto:
$29.05M
1 W Prestazione:
+2.39%
1M Prestazione:
+6.37%
6M Prestazione:
-35.56%
1 anno Prestazione:
+18.51%
Intervallo 1D:
$6.815
$7.02
Intervallo di 1 settimana:
$6.33
$7.21
Portata 52W:
$5.67
$14.38
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Confronta BVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.85 | 455.21M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
(BVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Do Options Traders Know Something About Bioventus Stock We Don't? - The Globe and Mail
(BVS) Proactive Strategies - news.stocktradersdaily.com
Bone Growth Stimulator Market Booming Worldwide with - openPR.com
bioventus inc. reports results of annual stockholders meeting By Investing.com - Investing.com South Africa
bioventus inc. reports results of annual stockholders meeting - Investing.com
Bioventus Holds Annual Meeting, Elects Directors - TipRanks
Cetera Investment Advisers Sells 1,805 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus’ Cut Losses 46%, Organic Sales Up 5% - Orthopedics This Week
Millennium Management LLC Sells 60,811 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Janus Henderson Group PLC Acquires Shares of 17,200 Bioventus Inc. (NYSE:BVS) - Defense World
Balyasny Asset Management L.P. Invests $133,000 in Bioventus Inc. (NYSE:BVS) - Defense World
BNP Paribas Financial Markets Invests $1.66 Million in Bioventus Inc. (NYSE:BVS) - Defense World
Price T Rowe Associates Inc. MD Has $160,000 Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
(BVS) On The My Stocks Page - news.stocktradersdaily.com
Bioventus reiterates 2025 guidance with focus on growth and profitability - MSN
Barclays PLC Has $696,000 Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus (BVS) Price Target Trimmed by Craig-Hallum Analyst | BVS Stock News - GuruFocus
Bioventus Inc. (NASDAQ:BVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Bioventus (NASDAQ:BVS) Using Too Much Debt? - simplywall.st
Bioventus First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures - Yahoo Finance
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures By GuruFocus - Investing.com Canada
Bioventus Reports Q1 2025 Financial Performance - TipRanks
Bioventus: Q1 Earnings Snapshot - CTPost
Bioventus Earnings Call: Growth Amid Challenges - TipRanks
Financial Fitness Check: Examining Bioventus Inc (BVS)’s Key Ratios - DWinneX
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Bioventus Q1 2025 slides: 5% organic growth despite revenue decline, maintains guidance - Investing.com Canada
Earnings call transcript: Bioventus Q1 2025 beats EPS forecast but faces stock dip - Investing.com Nigeria
Bioventus Inc. Q1 Loss Narrows - Nasdaq
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Bioventus (BVS) Exceeds Q1 Revenue Expectations with Strong Perf - GuruFocus
Bioventus Inc Q1 2025 Earnings: Revenue Hits $123.9M, Beating Es - GuruFocus
Bioventus (BVS) Exceeds Q1 Revenue Expectations with Strong Performance | BVS Stock News - GuruFocus
Bioventus reports Q1 revenue and earnings above estimates, shares dip By Investing.com - Investing.com Nigeria
Bioventus reports Q1 revenue and earnings above estimates, shares dip - Investing.com Australia
Bioventus Reports First Quarter Financial Results | BVS Stock Ne - GuruFocus
Bioventus Reports First Quarter Financial Results - The Manila Times
Bioventus Reports First Quarter Financial Results | BVS Stock News - GuruFocus
Bioventus Inc. Reports Q1 2025 Financial Results: Revenue Decline of 4.3% but Organic Growth of 5.0% and Improved Non-GAAP EPS - Nasdaq
Bioventus Inc. SEC 10-Q Report - TradingView
(BVS) Trading Report - news.stocktradersdaily.com
Examining the Future: Bioventus's Earnings Outlook - Nasdaq
Bioventus Inc (BVS) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bioventus Inc Azioni (BVS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bartholdson John A. | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
72,045 |
| SUTTER MARTIN P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| STALNECKER SUSAN M | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
105,957 |
| NOHRA GUY P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
126,610 |
| NEELS GUIDO J | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| McMurry-Heath Michelle | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
74,698 |
| Ladone Mary Kay | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
78,981 |
| HAWKINS WILLIAM A | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
257,851 |
| Beyer Pat | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
76,436 |
| Singleton Mark Leonard | SVP & CFO |
Apr 11 '25 |
Sale |
7.57 |
3,875 |
29,334 |
141,088 |
0.54%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):